Table 5 Costs, life expectancies, and quality adjusted life years (QALYs) for patients with oesophageal or gastric cardia cancer who had undergone all staging investigations (n=264)
Supraclavicular lymph nodes | Celiac lymph nodes | Liver | Lung | Number of patients with operation (%) | Costs per patient (k$) | Life expectancy per patient (year) | QALY per patient | Δ Costs/Δ QALY (k$ per QALY) |
|---|---|---|---|---|---|---|---|---|
CT | CT | CT | CT | 221/264 (84) | 41.9 | 1.973 | 1.178 | Dominated |
+USn: 1 pos | CT | CT | CT | 210/264 (80) | 39.8 | 1.966 | 1.176 | Reference |
+USn: 1 pos | CT | +USa: 2 pos | CT | 217/264 (82) | 41.1 | 1.993 | 1.190 | 94,7 |
+USn: 1 pos | CT | +USa: 2 pos | +CXR: | 222/264 (84) | 42.0 | 2.010 | 1.198 | 113,3 |
Surgery in all patients | 2 pos | 264/264 (100) | 50.0 | 2.033 | 1.204 | 365,3 | ||
